Objective: The role of pathology has evolved from the first microscopic definitions of diseases by Virchow to the new concept of molecular cytopathology. The management of diseases is now a multidisciplinary approach with the translation of morphological, imagery and molecular findings to therapeutic protocols. Obtaining the most reliable diagnostic material is the essential part of the medical management of patients. Study Design: Here, we try to gain a concise insight into the available data regarding the role of cytology in the application of molecular techniques, focusing on cancer cytopathology. Results: Obtaining cytological material is now feasible by different methods, and in some cases it is the only possible approach to a lesion which is not easily accessible for tissue sampling. The methods of obtaining cytological material have evolved in recent years in parallel with rapid advances in high-throughput molecular techniques, opening new windows for the diagnosis and management of diseases. Conclusions: Different kinds of cytological material are reliable for the application of molecular techniques. Cytological material obtained in a liquid base has advantages such as the better preservation of cytomorphological features and the use of the remaining liquid for nucleic acid extraction even after long storage and the application of molecular methods.

Keywords:
Fine-needle aspiration, Liquid-based cytology, Molecular techniques
1.
Fadda G, Rossi ED: Liquid-based cytology in fine-needle aspiration biopsies of the thyroid gland. Acta Cytol 2011;55:389-400.
2.
Schmitt FC, Longatto-Filho A, Valent A, Vielh P: Molecular techniques in cytopathology practice. J Clin Pathol 2008;61:258-267.
3.
Schmitt FC, Vielh P: Molecular biology and cytopathology. Principles and applications. Ann Pathol 2012;32:e57-e63, 444-450.
4.
Schmitt FC: Molecular cytopathology and flow cytometry: pre-analytical procedures matter. Cytopathology 2011;22:355-357.
5.
Ryu HS, Park IA, Park SY, Jung YY, Park SH, Shin HC: A pilot study evaluating liquid-based fine needle aspiration cytology of breast lesions: a cytomorphological comparison of SurePath® liquid-based preparations and conventional smears. Acta Cytol 2013;57:391-399.
6.
Geers C, Bourgain C: Liquid-based FNAC of the thyroid: a 4-year survey with SurePath. Cancer Cytopathol 2011;119:58-67.
7.
Tisserand P, Fouquet C, Marck V, Mallard C, Fabre M, Vielh P, Soussi T: ThinPrep-processed fine-needle samples of breast are effective material for RNA- and DNA-based molecular diagnosis: application to p53 mutation analysis. Cancer 2003;99:223-232.
8.
Rossi ED, Schmitt F: Pre-analytic steps for molecular testing on thyroid fine-needle aspirations: the goal of good results. Cytojournal 2013;10:24.
9.
Kim Y, Choi KR, Chae MJ, Shin BK, Kim HK, Kim A, Kim BH: Stability of DNA, RNA, cytomorphology, and immunoantigenicity in residual ThinPrep specimens. APMIS 2013;121:1064-1072.
10.
Dejmek A, Zendehrokh N, Tomaszewska M, Edsjo A: Preparation of DNA from cytological material: effects of fixation, staining, and mounting medium on DNA yield and quality. Cancer Cytopathol 2013;121:344-353.
11.
Jing X, Wey E, Michael CW: Diagnostic value of fine needle aspirates processed by ThinPrep® for the assessment of axillary lymph node status in patients with invasive carcinoma of the breast. Cytopathology 2013;24:372-376.
12.
Monaco SE, Wu Y, Teot LA, Cai G: Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas. Diagn Cytopathol 2013;41:308-315.
13.
Beraki E, Sauer T: Determination of HER-2 status on FNAC material from breast carcinomas using in situ hybridization with dual chromogen visualization with silver enhancement (dual SISH). Cytojournal 2010;7:21.
14.
Sauer T, Ebeltoft K, Pedersen MK, Karesen R: Liquid-based material from fine needle aspirates from breast carcinomas offers the possibility of long-time storage without significant loss of immunoreactivity of estrogen and progesterone receptors. Cytojournal 2010;7:24.
15.
Uzan C, Andre F, Scott V, Laurent I, Azria E, Suciu V, Balleyguier C, Lacroix L, Delaloge S, Vielh P: Fine-needle aspiration for nucleic acid-based molecular analyses in breast cancer. Cancer 2009;117:32-39.
16.
Bofin AM, Ytterhus B, Martin C, O'Leary JJ, Hagmar BM: Detection and quantitation of HER-2 gene amplification and protein expression in breast carcinoma. Am J Clin Pathol 2004;122:110-119.
17.
Ladd AC, O'Sullivan-Mejia E, Lea T, Perry J, Dumur CI, Dragoescu E, Garrett CT, Powers CN: Preservation of fine-needle aspiration specimens for future use in RNA-based molecular testing. Cancer Cytopathol 2011;119:102-110.
18.
Pegolo E, Machin P, Riosa F, Bassini A, Deroma L, Di Loreto C: Hormone receptor and human epidermal growth factor receptor 2 status evaluation on ThinPrep specimens from breast carcinoma: correlation with histologic sections determination. Cancer Cytopathol 2012;120:196-205.
19.
Nishimura R, Aogi K, Yamamoto T, Takabatake D, Takashima S, Teramoto N, Kagawa A, Morita S: Usefulness of liquid-based cytology in hormone receptor analysis of breast cancer specimens. Virchows Arch 2011;458:153-158.
20.
Chang MC, Crystal P, Colgan TJ: The evolving role of axillary lymph node fine-needle aspiration in the management of carcinoma of the breast. Cancer Cytopathol 2011;119:328-334.
21.
Chang MC, Escallon JM, Colgan TJ: Prognostic significance of a positive axillary lymph node fine-needle aspirate in patients with invasive breast carcinoma. Cancer Cytopathol 2014;122:138-144.
22.
Fischer AH, Clayton AC, Bentz JS, Wasserman PG, Henry MR, Souers RJ, Moriarty AT: Performance differences between conventional smears and liquid-based preparations of thyroid fine-needle aspiration samples: Analysis of 47,076 responses in the College of American Pathologists Interlaboratory Comparison Program in Non-Gynecologic Cytology. Arch Pathol Lab Med 2013;137:26-31.
23.
Rossi ED, Zannoni GF, Moncelsi S, Stigliano E, Santeusanio G, Lombardi CP, Pontecorvi A, Fadda G: Application of liquid-based cytology to fine-needle aspiration biopsies of the thyroid gland. Front Endocrinol (Lausanne) 2012;3:57.
24.
Cavaliere A, Colella R, Puxeddu E, Gambelunghe G, Avenia N, d'Ajello M, Cartaginese F, Vitali R, Bellezza G, Giansanti M, Sidoni A, De Feo P: Fine needle aspiration cytology of thyroid nodules: conventional vs thin layer technique. J Endocrinol Invest 2008;31:303-308.
25.
Lee JS, Choi HS, Park IA, Ryu HS: Liquid-based fine needle aspiration biopsy of papillary thyroid carcinoma: logistic regression analysis with conventional and new cytomorphologic features. Acta Cytol 2013;57:233-240.
26.
Rossi ED, Martini M, Capodimonti S, Straccia P, Cenci T, Lombardi CP, Pontecorvi A, Larocca LM, Fadda G: Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. Eur J Endocrinol 2013;168:853-859.
27.
Rossi ED, Raffaelli M, Zannoni GF, Pontecorvi A, Mule A, Calla C, Lombardi CP, Fadda G: Diagnostic efficacy of conventional as compared to liquid-based cytology in thyroid lesions: evaluation of 10,360 fine needle aspiration cytology cases. Acta Cytol 2009;53:659-666.
28.
Cibas ES, Ali SZ: The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 2009;132:658-665.
29.
Rossi ED, Raffaelli M, Minimo C, Mule A, Lombardi CP, Vecchio FM, Fadda G: Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer 2005;105:87-95.
30.
Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL: Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001;14:338-342.
31.
Ratour J, Polivka M, Dahan H, Hamzi L, Kania R, Dumuis ML, Cohen R, Laloi-Michelin M, Cochand-Priollet B: Diagnosis of follicular lesions of undetermined significance in fine-needle aspirations of thyroid nodules. J Thyroid Res 2013;2013:250347.
32.
Cochand-Priollet B, Dahan H, Laloi-Michelin M, Polivka M, Saada M, Herman P, Guillausseau PJ, Hamzi L, Poté N, Sarfati E, Wassef M, Combe H, Raulic-Raimond D, Chedin P, Medeau V, Casanova D, Kania R: Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control. Thyroid 2011;21:1067-1073.
33.
Chang H, Lee H, Yoon SO, Kim H, Kim A, Kim BH: BRAF (V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma. Hum Pathol 2012;43:89-95.
34.
Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio I, Fagin JA, Nikiforov YE, Troncone G, Palombini L, Basolo F, Santoro M: Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004;89:5175-5180.
35.
Musholt TJ, Fottner C, Weber MM, Eichhorn W, Pohlenz J, Musholt PB, Springer E, Schad A: Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg 2010;34:2595-2603.
36.
Rossi ED, Martini M, Capodimonti S, Lombardi CP, Pontecorvi A, Vellone VG, Zannoni GF, Larocca LM, Fadda G: BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. Cancer Cytopathol 2013;121:291-297.
37.
Nikiforova MN, Nikiforov YE: Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83-95.
38.
Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-762.
39.
Asioli S, Erickson LA, Sebo TJ, Zhang J, Jin L, Thompson GB, Lloyd RV: Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases. Am J Surg Pathol 2010;34:44-52.
40.
Lee SH, Jung CK, Bae JS, Jung SL, Choi YJ, Kang CS: Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma. Diagn Cytopathol 2014;42:11-17.
41.
Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH, Cho BY, Park do J: The association of the BRAF (V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012;118:1764-1773.
42.
Danilovic DL, Lima EU, Domingues RB, Brandao LG, Hoff AO, Marui S: Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. Eur J Endocrinol 2014;170:619-625.
43.
Rodrigues HG, de Pontes AA, Adan LF: Use of molecular markers in samples obtained from preoperative aspiration of thyroid. Endocr J 2012;59:417-424.
44.
Fadda G, Rossi ED, Raffaelli M, Pontecorvi A, Sioletic S, Morassi F, Lombardi CP, Zannoni GF, Rindi G: Follicular thyroid neoplasms can be classified as low- and high-risk according to HBME-1 and galectin-3 expression on liquid-based fine-needle cytology. Eur J Endocrinol 2011;165:447-453.
45.
Keutgen XM, Filicori F, Fahey TJ 3rd: Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev Mol Diagn 2013;13:613-623.
46.
A genomics-based classification of human lung tumors. Sci Transl Med 2013;5:3006802.
47.
Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-1075.
48.
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, Powell CA, Beer D, Riely G, Garg K, Austin JH, Rusch VW, Hirsch FR, Jett J, Yang PC, Gould M: International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc 2011;8:381-385.
49.
da Cunha Santos G, Saieg MA, Geddie W, Leighl N: EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011;119:80-91.
50.
Petriella D, Galetta D, Rubini V, Savino E, Paradiso A, Simone G, Tommasi S: Molecular profiling of ThinPrep FNA samples in assisting clinical management of non-small-cell lung cancer. Mol Biotechnol 2013;54:913-919.
51.
Malapelle U, de Rosa N, Rocco D, Bellevicine C, Crispino C, Illiano A, Piantedosi FV, Nappi O, Troncone G: EGFR and kRAS mutations detection on lung cancer liquid-based cytology: a pilot study. J Clin Pathol 2012;65:87-91.
52.
Malapelle U, de Rosa N, Bellevicine C, Rocco D, Vitiello F, Piantedosi FV, Illiano A, Nappi O, Troncone G: EGFR mutations detection on liquid-based cytology: is microscopy still necessary? J Clin Pathol 2012;65:561-564.
53.
Reis-Filho JS, de Lander Schmitt FC: Fluorescence in situ hybridization, comparative genomic hybridization, and other molecular biology techniques in the analysis of effusions. Diagn Cytopathol 2005;33:294-299.
54.
Savic S, Franco N, Grilli B, Barascud Ade V, Herzog M, Bode B, Loosli H, Spieler P, Schonegg R, Zlobec I, Clark DP, Herman JG, Bubendorf L: Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest 2010;138:137-144.
55.
Onofre FB, Onofre AS, Pomjanski N, Buckstegge B, Grote HJ, Bocking A: 9p21 deletion in the diagnosis of malignant mesothelioma in serous effusions additional to immunocytochemistry, DNA-ICM, and AgNOR analysis. Cancer 2008;114:204-215.
56.
Todenhofer T, Hennenlotter J, Esser M, Mohrhardt S, Tews V, Aufderklamm S, Gakis G, Kuehs U, Stenzl A, Schwentner C: Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol 2013;121:252-260.
57.
Dimashkieh H, Wolff DJ, Smith TM, Houser PM, Nietert PJ, Yang J: Evaluation of uroVysion and cytology for bladder cancer detection: a study of 1,835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol 2013;121:591-597.
58.
Eloubeidi MA, Khan AS, Luz LP, Linder A, Moreira DM, Crowe DR, Eltoum IA: Combined use of EUS-guided FNA and immunocytochemical stains discloses metastatic and unusual diseases in the evaluation of mediastinal lymphadenopathy of unknown etiology. Ann Thorac Med 2012;7:84-91.
59.
Lazar A, Abruzzo LV, Pollock RE, Lee S, Czerniak B: Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas. Arch Pathol Lab Med 2006;130:1199-1207.
60.
Klijanienko J, Couturier J, Bourdeaut F, Freneaux P, Ballet S, Brisse H, Lagace R, Delattre O, Pierron G, Vielh P, Sastre-Garau X, Michon J: Fine-needle aspiration as a diagnostic technique in 50 cases of primary Ewing sarcoma/peripheral neuroectodermal tumor. Institut Curie's experience. Diagn Cytopathol 2012;40:19-25.
61.
Gomes AL, Bardales RH, Milanezi F, Reis RM, Schmitt F: Molecular analysis of c-KIT and PDGFRA in GISTs diagnosed by EUS. Am J Clin Pathol 2007;127:89-96.
62.
Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R, Salto-Tellez M: KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. Cytopathology 2011;22:358-364.
63.
Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S, Gugenheim J, Becouarn Y, Brunet R, Fonck M, Francois E, Saint-Paul MC, Pedeutour F: KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol 2010;17:1429-1434.
64.
Raica M, Cimpean AM, Ceausu RA, Fulga V, Nica C, Rudico L, Saptefrati L: Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both? Anticancer Res 2014;34:1435-1440.
65.
Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nole F: A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 2014;50:277-289.
66.
Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 2012;30:2601-2608.
67.
Burel-Vandenbos F, Ambrosetti D, Coutts M, Pedeutour F: EGFR mutation status in brain metastases of non-small cell lung carcinoma. J Neurooncol 2013;111:1-10.
68.
Ruppert AM, Beau-Faller M, Neuville A, Guerin E, Voegeli AC, Mennecier B, Legrain M, Molard A, Jeung MY, Gaub MP, Oudet P, Quoix E: EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J 2009;33:436-440.
69.
Malaviya AA, Chinoy RF, Prabhudesai NM, Sawant MH, Parmar V, Badwe RA: Immunocytochemistry on scrape cytology in breast cancer: will it unearth the weaker positives? Acta Cytol 2006;50:284-290.
70.
Ferguson J, Chamberlain P, Cramer HM, Wu HH: ER, PR, and HER2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies. Diagn Cytopathol 2013;41:575-581.
71.
Minca EC, Lanigan CP, Reynolds JP, Wang Z, Ma PC, Cicenia J, Almeida FA, Pennell NA, Tubbs RR: ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material. J Thorac Oncol 2014;9:464-468.
72.
Neat MJ, Foot NJ, Hicks A, Breen R, Wilkins B, McLean E, Santis G: ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer. Cytopathology 2013;24:356-364.
73.
Betz BL, Dixon CA, Weigelin HC, Knoepp SM, Roh MH: The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma. Cancer Cytopathol 2013;121:489-499.
74.
Colasacco C, Mount S, Leiman G: Documentation of immunocytochemistry controls in the cytopathologic literature: a meta-analysis of 100 journal articles. Diagn Cytopathol 2011;39:245-250.
75.
Hansen T, Pedersen H, Brauner V, Hariri J: Control specimens for immunocytochemistry in liquid-based cytology. Cytopathology 2011;22:243-246.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.